ICWEA Statement on Gilead Sciences’ Licensing of Lenacapavir: A Step Toward Expanding HIV Prevention Choices Read More
ICWEA Statement on Gilead’s announcement of twice-yearly Lenacapavir (LEN) for HIV prevention. Read More
